Accueil › Cancer du pancréas › Caroline du Nord › Durham
Essais cliniques pour Cancer du pancréas à Durham, NC
24 études pour Cancer du pancréas recherchent des participants dans et autour de Durham (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
The Vanguard Study: Testing a New Way to Screen for Cancer
Recrutement en coursVolontaires sains bienvenus
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
A Study of PHN-012 in Patients With Advanced Solid Tumors
Recrutement en coursPhase 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Recrutement en coursPhase 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
Recrutement en coursÉtude observationnelle
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Recrutement en coursPhase 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · à 10 mi
- University of North Carolina Hospitals at Hillsborough, Hillsborough · à 13 mi
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Recrutement en coursPhase 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Recrutement en coursPhase 3
- Investigative Site US035, Chapel Hill · à 10 mi
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Recrutement en coursPhase 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Recrutement en coursPhase 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Recrutement en cours
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Recrutement en coursÉtude observationnelle
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
- University of North Carolina-Hillsborough Campus, Hillsborough · à 13 mi
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Recrutement en coursPhase 2
- University of North Carolina, Chapel Hill · à 10 mi
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Recrutement en coursPhase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · à 10 mi
- University of North Carolina, Chapel Hill · à 10 mi
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Recrutement en coursPhase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Recrutement en coursPhase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Recrutement en coursPhase 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Recrutement en coursPhase 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Recrutement en coursPhase 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Recrutement en coursPhase 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Recrutement en coursPhase 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Recrutement en coursPhase 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Recrutement en coursPhase 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · à 10 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Chapel Hill · à 10 mi
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Recrutement en coursPhase 2
- University of North Carolina, Chapel Hill · à 10 mi
Essais pour Cancer du pancréas dans d'autres villes
- Houston, TX61 études
- New York City, NY60 études
- Boston, MA43 études
- Nashville, TN39 études
- Los Angeles, CA35 études
- St. Louis, MO33 études
- Arlington, VA33 études
- Baltimore, MD31 études
- San Antonio, TX31 études
- Philadelphia, PA26 études
- Tampa, FL26 études
- San Diego, CA24 études
Autres études à Durham
- Cancer du sein64 études
- Cancer (tous types)58 études
- Cancer du poumon non à petites cellules39 études
- Myélome multiple37 études
- Leucémie aiguë myéloïde33 études
- Cancer métastatique33 études
- Cancer de la prostate32 études
- Cancer du poumon32 études
- Cancer colorectal28 études
- Cancer de l'ovaire27 études
- Leucémie lymphocytaire chronique27 études
- Insuffisance cardiaque26 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.